Plasminogen in the prevention of hyaline membrane disease
| Autor: | Henry P. Staub, Irwin D. J. Bross, Okhee S. Jung, Michael Ray, Dean Goplerud, Robert V. Moesch, Clara M. Ambrus, Ronald J. Foote, Bernard Eisenberg, David H. Weintraub, Thai S. Choi, Irving B. Mink, Norman G. Courey, Julian L. Ambrus |
|---|---|
| Rok vydání: | 1974 |
| Předmět: |
medicine.medical_specialty
Umbilical Veins Fibrin deposition medicine.medical_treatment Hyaline Membrane Disease Disease Placebo Fibrin law.invention Placebos Randomized controlled trial law Internal medicine Fibrinolysis Medicine Birth Weight Humans Hyaline Clinical Trials as Topic Respiratory Distress Syndrome Newborn biology Respiratory distress business.industry Infant Newborn Plasminogen Surgery Pulmonary Alveoli Pediatrics Perinatology and Child Health Injections Intravenous biology.protein business Respiratory Insufficiency |
| Zdroj: | American journal of diseases of children (1960). 127(2) |
| ISSN: | 0002-922X |
| Popis: | Alveolar hyaline membranes in hyaline membrane disease (HMD) consist partly of fibrin. Premature infants lack serum plasminogen, thus they are unable to develop effective fibrinolysis and are defenseless against fibrin deposition. Therefore, plasminogen was tested for the prevention of HMD. In a double-blind randomized study, 100 infants between 1.0 and 2.5 kg birthweight received plasminogen or placebo soon after birth. Factors placing the infant at risk from HMD were found to be evenly divided between control and treated groups. Among the 51 infants who received placebo, seven developed mild, and ten developed severe respiratory distress; of these ten, five died with HMD. Two infants died from causes other than HMD. Among the 49 infants treated with plasminogen, 13 developed mild and three developed severe respiratory distress. There was no death due to HMD. Two deaths were due to other causes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|